Pfizer lanza estas ayudas para la financiación de hasta cinco proyectos relacionados con COVID-19 en las siguientes temáticas:
- Societal impact of COVID-19. Understand the psychological impact, impact on working behaviors, social determinants of health, child development, education, access to healthcare, healthcare resource utilization, direct and indirect costs and impact on QoL
- Key populations at high-risk of severe COVID-19 outcomes. Further understand impact of COVID-19 in high-risk population groups, especially in immunocompromised and elderly patients and in patients with multiple co-morbidities.
- Long term outcomes of COVID-19. Studies assessing long-term or secondary consequences of the disease, including impact of reinfection and effects of different variants (includes but not exclusive to Long COVID/ post-acute sequelae of SARS CoV-2 infection (PASC))
- Treatment of mild-to-moderate COVID-19 in vaccinated and or seropositive patients with nirmatrelvir/ritonavir.
- Impact of treatment for mild-to-moderate COVID-19 with nirmatrelvir/ritonavir on viral load, infectivity and/or transmission and/or viral rebound and/or symptom resolution
- Regarding use of nirmatrelvir/ritonavir and showing outcomes: prescription behaviors (reason for non-prescription), patient refusal reasons, access and adherence to treatment.
Requisitos de los Solicitantes:
La convocatoria es de carácter global y solicitudes podrán ser presentadas por organizaciones de cualquier país.
Requisitos del IP:
Las propuestas deberán estar lideradas por un Investigador Principal, vinculado a la institución solicitante, que tenga el título de Doctor o Médico especialista (MD, PhD, o equivalente), un título de enfermería avanzado (BSN con MS / PhD), o un título en Farmacia, Fisioterapia o Trabajo Social.
es
EN
